Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 22 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Gufic BioSciences Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 21, 2024, 10:07 pm

Market Cap 4,089 Cr.
Current Price 406
High / Low504/278
Stock P/E48.1
Book Value 57.3
Dividend Yield0.02 %
ROCE17.2 %
ROE20.0 %
Face Value 1.00
PEG Ratio1.99

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Gufic BioSciences Ltd

Competitors of Gufic BioSciences Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Industry Average0 Cr0000%0.59%0.49%0

All Competitor Stocks of Gufic BioSciences Ltd

Quarterly Result

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales128167132251194172162165175177173195215
Expenses99139108205158139130132142143141160176
Operating Profit29272446363333333334323539
OPM %23%16%18%18%18%19%20%20%19%19%19%18%18%
Other Income2011020011110
Interest4431211122344
Depreciation5344445456644
Profit before tax23201742302926282727242831
Tax %25%24%25%25%23%27%23%26%26%25%24%26%25%
Net Profit17151331232120212020182123
EPS in Rs2.231.991.653.222.412.172.092.172.082.101.872.132.39

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales8198121148201245306351379488779691785
Expenses7487109134181222267305327404631556641
Operating Profit7111214202339465284148135143
OPM %9%11%10%10%10%9%13%13%14%17%19%20%18%
Other Income0011114464332
Interest34446691014145815
Depreciation222444451416192219
Profit before tax3567101430353058127107112
Tax %49%37%32%36%29%37%45%38%25%23%24%25%
Net Profit23447916222344968084
EPS in Rs0.200.430.550.540.951.172.132.822.925.689.898.228.61
Dividend Payout %25%12%9%9%5%4%2%2%2%2%1%1%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)50.00%33.33%0.00%75.00%28.57%77.78%37.50%4.55%91.30%118.18%-16.67%
Change in YoY Net Profit Growth (%)0.00%-16.67%-33.33%75.00%-46.43%49.21%-40.28%-32.95%86.76%26.88%-134.85%

Gufic BioSciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:21%
5 Years:18%
3 Years:18%
TTM:6%
Compounded Profit Growth
10 Years:35%
5 Years:32%
3 Years:26%
TTM:3%
Stock Price CAGR
10 Years:37%
5 Years:44%
3 Years:29%
1 Year:34%
Return on Equity
10 Years:27%
5 Years:27%
3 Years:27%
Last Year:20%

Last Updated: Unknown

Balance Sheet

Last Updated: Unknown

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Equity Capital88888881010101010
Reserves15181926304668120164259338523
Borrowings353333435780981266264334333
Other Liabilities3252677584104106152157188179227
Total Liabilities901111271521782382804083925218611,093
Fixed Assets2730252222232483100115160159
CWIP30000210311341170307
Investments000000000012
Other Assets6081102130156213245294279365531625
Total Assets901111271521782382804083925218611,093

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +51111-4-4-554787106-27-7
Cash from Investing Activity +-13-3-2-1-5-9-13-43-7-95-191-102
Cash from Financing Activity +8-7-557148-4-79-623482
Net Cash Flow014-0-11-002517-27

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow7.00-24.00-21.00-19.00-23.00-34.00-41.00-52.00-74.0022.0084.00-199.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days75858210278971071039371109149
Inventory Days143144165180190238190249138102202188
Days Payable144176223188132192157238162125143156
Cash Conversion Cycle745425941361431411146948167181
Working Capital Days71644876841091281108058136173
ROCE %18%17%18%24%24%33%30%21%29%46%23%17%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters75.48%75.48%75.48%75.00%75.00%75.00%75.00%75.00%75.00%72.51%72.51%72.51%
FIIs1.52%1.69%1.51%1.38%0.06%0.16%0.72%0.70%0.72%0.47%0.12%0.23%
DIIs2.13%1.19%1.12%1.13%1.16%1.16%1.16%1.16%1.63%1.72%2.20%2.38%
Public20.87%21.64%21.89%22.49%23.76%23.67%23.12%23.12%22.64%25.29%25.17%24.89%
No. of Shareholders35,13534,58038,14440,12041,37640,56238,90238,62436,55734,42434,69532,250

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
SBI Healthcare Opportunities Fund1,000,0001.3226.08438,6032024-11-20128%
Quant Business Cycle Fund438,6031.7811.44438,6032024-11-200%
Motilal Oswal Nifty Microcap 250 Index Fund23,0730.130.6438,6032024-11-20-94.74%
Motilal Oswal S&P BSE Healthcare ETF2470.080.01438,6032024-11-20-99.94%
Groww Nifty Total Market Index Fund5300438,6032024-11-20-99.99%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24
FaceValue1.00
Basic EPS (Rs.)8.74
Diluted EPS (Rs.)8.74
Cash EPS (Rs.)10.29
Book Value[Excl.RevalReserv]/Share (Rs.)53.11
Book Value[Incl.RevalReserv]/Share (Rs.)53.11
Revenue From Operations / Share (Rs.)80.44
PBDIT / Share (Rs.)14.76
PBIT / Share (Rs.)13.07
PBT / Share (Rs.)11.54
Net Profit / Share (Rs.)8.59
NP After MI And SOA / Share (Rs.)8.59
PBDIT Margin (%)18.35
PBIT Margin (%)16.24
PBT Margin (%)14.33
Net Profit Margin (%)10.67
NP After MI And SOA Margin (%)10.67
Return on Networth / Equity (%)16.17
Return on Capital Employeed (%)18.18
Return On Assets (%)7.88
Long Term Debt / Equity (X)0.28
Total Debt / Equity (X)0.59
Current Ratio (X)1.61
Quick Ratio (X)1.08
Dividend Payout Ratio (NP) (%)1.12
Dividend Payout Ratio (CP) (%)0.93
Earning Retention Ratio (%)98.88
Cash Earning Retention Ratio (%)99.07
Interest Coverage Ratio (X)9.64
Interest Coverage Ratio (Post Tax) (X)6.61
Enterprise Value (Cr.)3142.92
EV / Net Operating Revenue (X)3.90
EV / EBITDA (X)21.23
MarketCap / Net Operating Revenue (X)3.52
Retention Ratios (%)98.87
Price / BV (X)5.33
Price / Net Operating Revenue (X)3.52
EarningsYield0.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Gufic BioSciences Ltd as of November 22, 2024 is: 551.34

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 22, 2024, Gufic BioSciences Ltd is Undervalued by 35.80% compared to the current share price 406.00

Intrinsic Value of Gufic BioSciences Ltd as of November 22, 2024 is: 684.45

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 22, 2024, Gufic BioSciences Ltd is Undervalued by 68.58% compared to the current share price 406.00

Last 5 Year EPS CAGR: 24.14%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 25.00%, which is a positive sign.
  2. The company has higher reserves (135.50 cr) compared to borrowings (108.17 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (359.46 cr) and profit (41.85 cr) over the years.
  1. The stock has a high average Working Capital Days of 94.75, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 103.83, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gufic BioSciences Ltd:
    1. Net Profit Margin: 10.67%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 18.18% (Industry Average ROCE: 0.59%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 16.17% (Industry Average ROE: 0.49%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 6.61
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.08
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 48.1 (Industry average Stock P/E: 0)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.59
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Gufic BioSciences Ltd. is a Public Limited Listed company incorporated on 23/07/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1984PLC033519 and registration number is 033519. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 779.16 Cr. and Equity Capital is Rs. 9.69 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals37, First Floor, Kamala Bhavan II, Mumbai Maharashtra 400069corporaterelations@guficbio.com
http://www.gufic.com
Management
NamePosition Held
Mr. Jayesh P ChoksiChairman & Managing Director
Mr. Pranav J ChoksiWholeTime Director & CEO
Mr. Pankaj J GandhiWhole Time Director
Mr. Dilip B GhoshWhole Time Director
Dr. Balram H SinghNon Exe.Non Ind.Director
Mr. Shreyas K PatelIndependent Director
Mr. Shrirang V VaidyaIndependent Director
Dr. Anu S AuoraIndependent Director
Dr. Rabi N SahooIndependent Director
Mr. Gopal M DaptariIndependent Director

FAQ

What is the latest intrinsic value of Gufic BioSciences Ltd?

The latest intrinsic value of Gufic BioSciences Ltd as on 22 November 2024 is ₹551.34, which is 35.80% higher than the current market price of ₹406.00.

What is the Market Cap of Gufic BioSciences Ltd?

The Market Cap of Gufic BioSciences Ltd is 4,089 Cr..

What is the current Stock Price of Gufic BioSciences Ltd as on 22 November 2024?

The current stock price of Gufic BioSciences Ltd as on 22 November 2024 is 406.

What is the High / Low of Gufic BioSciences Ltd stocks in FY 2024?

In FY 2024, the High / Low of Gufic BioSciences Ltd stocks is 504/278.

What is the Stock P/E of Gufic BioSciences Ltd?

The Stock P/E of Gufic BioSciences Ltd is 48.1.

What is the Book Value of Gufic BioSciences Ltd?

The Book Value of Gufic BioSciences Ltd is 57.3.

What is the Dividend Yield of Gufic BioSciences Ltd?

The Dividend Yield of Gufic BioSciences Ltd is 0.02 %.

What is the ROCE of Gufic BioSciences Ltd?

The ROCE of Gufic BioSciences Ltd is 17.2 %.

What is the ROE of Gufic BioSciences Ltd?

The ROE of Gufic BioSciences Ltd is 20.0 %.

What is the Face Value of Gufic BioSciences Ltd?

The Face Value of Gufic BioSciences Ltd is 1.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Gufic BioSciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE